R&D channel feed

Keep­ing pres­sure on Am­gen, Mi­rati draws mixed re­views on lat­est cut of KRAS da­ta

4 years ago

Roche's CD20xCD3 does­n't beat Gen­mab at ORR, but sets bar for CR da­ta on lym­phoma drug

4 years ago
Pharma

In search of elu­sive NASH break­through, Pfiz­er spot­lights com­bo ap­proach

4 years ago

Say­ing good­bye to R&D chief, Flag­ship-backed Ax­cel­la drops PhII pro­gram as it fo­cus­es on long Covid, NASH

4 years ago
People
Coronavirus

Plan­ning ahead for crowd­ed ul­cer­a­tive col­i­tis mar­ket, Pfiz­er spells out PhI­II da­ta on $6.7B Are­na drug

4 years ago

Pfiz­er spin­out Spring­Works will ship its first drug to the FDA be­fore year’s end with PhI­II win

4 years ago

A new era of treat­ment: How bio­mark­ers are chang­ing the way we think about can­cer

4 years ago
In Focus

Blam­ing Covid dis­rup­tion, sup­ply short­ages, mi­cro­cap biotech hits the brakes on cell ther­a­py tri­al

4 years ago
Cell/Gene Tx

Lil­ly's mirik­izum­ab, once a con­tender for pso­ri­a­sis, bol­sters case for UC in­di­ca­tion in main­te­nance tri­al da­ta read­out

4 years ago
Pharma

Idor­sia claims PhI­II win for hy­per­ten­sion drug at cen­ter of $230M J&J deal

4 years ago

'Xeno­trans­plan­ta­tion is com­ing': New NE­JM pa­per gives de­tailed look in­to 2 pig-to-hu­man kid­ney trans­plant cas­es

4 years ago

One tri­al down, one to go as Con­cert Phar­ma­ceu­ti­cals tunes up PhI­II win for alope­cia drug

4 years ago

Fresh off $11.6B sale to Pfiz­er, New Bio­haven hits Phase III set­back just weeks af­ter Vlad Coric chalked up promise

4 years ago

Ahead of FDA, EMA rec­om­mends au­tho­riz­ing new gene ther­a­py treat­ment for ul­tra-rare dis­ease

4 years ago
Cell/Gene Tx

Ather­sys tries to post-hoc-an­a­lyze its way out of an­oth­er tri­al fail for stroke stem cell ther­a­py

4 years ago
Cell/Gene Tx

Try­ing to shake up the Parkin­son's par­a­digm, Ab­b­Vie sub­mits NDA for con­tin­u­ous, 24-hour in­fu­sion ther­a­py

4 years ago
FDA+

Tout­ing 100% OS rate in piv­otal rare dis­ease tri­al, Rock­et Phar­ma ready to head to FDA

4 years ago
Cell/Gene Tx

Flag­ship's Foghorn, part­nered with Mer­ck and Eli Lil­ly, gets a par­tial FDA hold af­ter pa­tient death

4 years ago
FDA+

Bay­er sounds re­treat from a $670 mil­lion CAR-T pact in the wake of a pa­tient death

4 years ago
Deals

A year af­ter scor­ing FDA ap­proval for di­a­betes drug, Zealand touts pos­i­tive PhI­II da­ta for new in­di­ca­tion

4 years ago

NIH grants over $500M to cre­ate an­tivi­rals for fu­ture pan­demics

4 years ago

An­oth­er biotech that went pub­lic in pan­dem­ic boom aims to weath­er the bear mar­ket through R&D cut­backs

4 years ago
People

Go­ing for broke, Tri­ci­da is slam­ming the brakes on a piv­otal tri­al ear­ly while plan­ning a run at the FDA

4 years ago

As Big Phar­ma cir­cles RSV wag­ons, biotech re­ports mid-stage flop for its an­tivi­ral

4 years ago
First page Previous page 134135136137138139140 Next page Last page
A service from the Financial Times